Related Experiment Video
Updated: Jul 19, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases
Suhayl Dhib-Jalbut1, Douglas L Arnold, Don W Cleveland
1UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, and The Cleveland Clinic, OH, USA. jalbutsu@umdnj.edu
Abstract:
Multiple sclerosis is considered a disease of myelin destruction; Parkinson's disease (PD), one of dopaminergic neuron depletion; ALS, a disease of motor neuron death; and Alzheimer's, a disease of plaques and tangles. Although these disorders differ in important ways, they also have common pathogenic features, including inflammation, genetic mutations, inappropriate protein aggregates (e.g., Lewy bodies, amyloid plaques), and biochemical defects leading to apoptosis, such as oxidative stress and mitochondrial dysfunction. In most disorders, it remains uncertain whether inflammation and protein aggregation are neurotoxic or neuroprotective. Elucidating the mechanisms that orchestrate neuronal diseases should facilitate development of neuroprotective and neurorestorative strategies.
Related Concept Videos
Multiple Sclerosis l: Introduction
Parkinson's Disease: Overview
Neurogenesis and Regeneration of Nervous Tissue
The Blood-brain Barrier
Neural Regulation
Glial Cells
